Pazopanib Safe, Effective as Second-Line Treatment for Renal Cell Carcinoma
the Cancer Therapy Advisor take:
According to a new study published in the European Journal of Cancer, researchers in Guangzhou, China, have found that pazopanib was clinically active and well tolerated as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma.
For the multicentre, single-arm, phase 2 study, researchers sought to investigate the efficacy and safety of pazopanib as second-line treatment after sunitinib failure in patients with renal cell carcinoma and to identify potential biomarkers for pazopanib response.
Pazopanib is a selective multi-targeted receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration for advanced metastatic renal cell carcinoma and advanced soft tissue sarcomas. Researchers enrolled 86 patientss with metastatic clear cell renal cell carcinoma between 2009 and 2012 from three institutions in Southern China.
All patients received pazopanib 800mg daily. Results showed a median progression-free survival was 5.6 months (95% CI: 4.1 - 6.7). No complete responses were observed, but 15.3% (95% CI: 11.2 - 23.9) achieved partial responses.
In regard to safety, the most common adverse events were anemia, AST elevation, diarrhea, and hypertension, which were all mild to moderate and clinically manageable). Researchers identified DLL4, VEGFA, and HIF-2α as potential biomarkers of clinical efficacy for pazopanib.

Pazopanib was clinically active and well tolerated as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma.
Related Resources
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Prostate Cancer | Regimens | Drugs |
Rare Cancers | Regimens | |
Renal Cell Carcinoma | Regimens | Drugs |
Skin Cancer | Regimens | Drugs |
Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed